Abstract |
For breast cancer patients, treatment decisions based on the molecular profile of the primary tumor have been used for many years. In Her2-overexpressing tumors, trastuzumab is a key component of therapy. However, despite persistent expression of Her2, most tumors eventually become resistant to trastuzumab. When this happens, the patients benefit from a regime containing lapatinib, a dual EGFR and Her2 tyrosine kinase inhibitor. We report on a patient affected by chemo-refractory metastatic Her2-positive breast cancer enrolled in a translational research program for the detection and characterization of circulating tumor cells (CTCs). Depletion of the EGFR-positive CTC pool in the blood was associated with tumor response, whereas disease progression was related to a recurrence in CTCs, which were both EGFR and Her2 negative. Although a proof for the clinical significance of EGFR-positive circulating tumor cells is currently lacking, expression of EGFR may predict response to lapatinib-based treatments as in the case presented.
|
Authors | Zhian Liu, Alberto Fusi, Alexander Schmittel, Ingeborg Tinhofer, Achim Schneider, Ulrich Keilholz |
Journal | Cancer biology & therapy
(Cancer Biol Ther)
Vol. 10
Issue 9
Pg. 860-4
(Nov 01 2010)
ISSN: 1555-8576 [Electronic] United States |
PMID | 20855957
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Genetic Markers
- Protein Kinase Inhibitors
- Quinazolines
- Lapatinib
- Deoxycytidine
- Capecitabine
- ErbB Receptors
- Receptor, ErbB-2
- Trastuzumab
- Fluorouracil
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy, pathology)
- Capecitabine
- Deoxycytidine
(analogs & derivatives, therapeutic use)
- Disease Progression
- Drug Resistance, Neoplasm
- ErbB Receptors
(antagonists & inhibitors, metabolism)
- Female
- Flow Cytometry
- Fluorouracil
(analogs & derivatives, therapeutic use)
- Gene Expression Profiling
- Genetic Markers
- Humans
- Lapatinib
- Middle Aged
- Neoplasm Metastasis
- Neoplastic Cells, Circulating
(metabolism, pathology)
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
- Quinazolines
(therapeutic use)
- Receptor, ErbB-2
(antagonists & inhibitors, genetics, metabolism)
- Trastuzumab
|